Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
27 déc. 2024 08h05 HE
|
Outlook Therapeutics, Inc.
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in...
Outlook Therapeutics® Streamlines Operations
13 déc. 2024 16h30 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
04 déc. 2024 08h05 HE
|
Outlook Therapeutics, Inc.
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of...
Outlook Therapeutics® Announces Executive Leadership Transition
03 déc. 2024 16h30 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
27 nov. 2024 06h50 HE
|
Outlook Therapeutics, Inc.
Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
06 nov. 2024 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
17 oct. 2024 09h00 HE
|
Outlook Therapeutics, Inc.
Access the CEO Connect segment here ISELIN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the...
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
16 sept. 2024 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
13 sept. 2024 09h05 HE
|
Outlook Therapeutics, Inc.
Webcast replay of fireside chat now available ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory...
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
04 sept. 2024 08h35 HE
|
Outlook Therapeutics, Inc.
Topline results from NORSE EIGHT expected in Q4 CY2024 ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved...